Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) dropped 7.8% during mid-day trading on Tuesday . The company traded as low as $82.62 and last traded at $82.47. Approximately 11,643,962 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 13,738,480 shares. The stock had previously closed at $89.44.
Analyst Upgrades and Downgrades
Several analysts recently commented on TEM shares. Needham & Company LLC restated a "buy" rating and set a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. TD Cowen restated a "buy" rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Finally, Piper Sandler reissued a "neutral" rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $58.55.
View Our Latest Stock Analysis on TEM
Tempus AI Price Performance
The firm has a 50-day moving average price of $49.75 and a two-hundred day moving average price of $51.44. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.
Insiders Place Their Bets
In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the firm's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David R. Epstein sold 620 shares of the firm's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,583,467 shares of company stock worth $130,542,311 over the last three months.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Operose Advisors LLC bought a new stake in shares of Tempus AI during the 4th quarter worth $25,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI in the third quarter valued at about $30,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at about $34,000. Prestige Wealth Management Group LLC grew its stake in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI during the fourth quarter worth approximately $49,000. 24.22% of the stock is owned by institutional investors and hedge funds.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
